AspenBio Pharma, Inc. is an emerging in vitro diagnostic company focused on obtaining FDA clearance for its lead product, AppyScore, which is a unique blood-based test in development designed to help physicians manage the large number of patients who enter emergency rooms every year complaining of abdominal pain, many suspected of having acute appendicitis. AppyScore is a test to aid in evaluating patients suspected of appendicitis based on its projected high sensitivity and negative predictive value. The AppyScore test is designed to aid in identifying those patients who are at low risk for appendicitis, allowing clinicians to take a more conservative approach to patient management. The current focus of AspenBio’s effort is the use of AppyScore in children and adolescents suspicious for the disease as this population is at the highest risk for appendicitis as well having the highest risk of the long-term health effects associated with CT imaging. AppyScore could potentially decrease radiation exposure risk arising from the use of CT scans performed in triaging pediatric and adolescent patients with abdominal pain, as well as potentially reduce healthcare costs. The company has a large and unique repository of blood samples that may provide valuable data regarding the appendicitis condition and additional protein marker information associated with causes of abdominal pain, providing an important resource for product development. For more information, visit www.aspenbiopharma.com.
This press release includes "forward-looking statements" of AspenBio
Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange
Commission ("SEC"). All statements, other than statements of historical
fact, included in this press release that address activities, events or
developments that AspenBio believes or anticipates will or may occur in
the future are forward-looking statements. These statements are based on
certain assumptions made based on experience, expected future
developments and other factors AspenBio believes are appropriate in the
circumstances. Such statements are subject to a number of assumptions,
risks and uncertainties, many of which are beyond the control of
AspenBio. Investors are cautioned that any such statements are not
guarantees of future performance. Actual results or developments may
differ materially from those projected in the forward-looking statements
as a result of many factors, including our ability to successfully
complete required product development and modifications in a timely and
cost effective manner, complete clinical trial activities for
required for FDA submission, obtain FDA clearance or approval, cost
effectively manufacture and generate revenues from
other new products, execute agreements required to successfully advance
the company's objectives, retain the management team to advance the
products, overcome adverse changes in market conditions and the
regulatory environment, obtain and enforce intellectual property rights,
and realize value of intangible assets. Furthermore, AspenBio does not
intend (and is not obligated) to update publicly any forward-looking
statements. The contents of this press release should be considered in
conjunction with the risk factors contained in AspenBio's recent filings
with the SEC, including its Form S-1 filed on April 12, 2012.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV